Feruloylated oligosaccharides and ferulic acid alter gut microbiome to alleviate diabetic syndrome
Feruloylated oligosaccharides and ferulic acid alter gut microbiome to alleviate diabetic syndrome
复制标题
阿魏酰化寡糖和阿魏酸改变肠道微生物群以缓解糖尿病综合征
DOI：
10.1016/j.foodres.2020.109410
复制
发表时间：
2020-11-01
影响因子：
8.1
通讯作者：
Huang, Jun-qing
中科院分区：
文献类型：
--
作者：
Song, Yuan;Wu, Man-si;Huang, Jun-qing
肠道微生物群已被证明与 2 型糖尿病 (T2D) 的发生有关。此外，越来越多的证据表明肠道微生物组的组成与 T2D 治疗的结果高度相关。此前我们证明阿魏酰寡糖（FO）和阿魏酸（FA）可缓解大鼠糖尿病综合征，但详细机制尚未探索。在这项研究中，我们致力于通过使用 16S rRNA 高通量测序和气相色谱 (GC) 来描述 FO 和 FA 如何改变糖尿病大鼠的肠道微生物组和相关代谢组。我们的结果表明，FOs 降低了乳杆菌属、瘤胃球菌属、振荡杆菌属和脱硫弧菌属的丰度，但增加了阿克曼氏菌属、褐藻菌属和图里奇杆菌属的丰度。 FO 治疗大鼠的肠道微生物组结构与健康大鼠相似，而不是糖尿病大鼠。同样，FA减少了乳杆菌、瘤胃球菌的比例，但促进了拟杆菌属、布氏杆菌属、粪杆菌属、副拟杆菌属和葡萄杆菌属的生长。此外，短链脂肪酸 (SCFA) 和支链脂肪酸 (BCFA) 是肠道介导宿主葡萄糖代谢的主要细菌脂质代谢物，随着 FO 和 FA 治疗的进行，短链脂肪酸 (SCFA) 和支链脂肪酸 (BCFA) 显着升高。我们的研究结果表明，FO 和 FA 最有可能通过调节肠道微生物组的组成和代谢来减轻大鼠的糖尿病综合征。该研究为功能性食品抗糖尿病作用的机制提供了新的见解，并促进了糖尿病患者膳食补充剂的开发。
Gut microbiome has been proven to be involved in the development of type 2 diabetes (T2D). Additionally, increasing evidence showed that the composition of gut microbiome is highly associated with the outcome of T2D therapy. Previously we demonstrated that feruloylated oligosaccharides (FOs) and ferulic acid (FA) alleviated diabetic syndrome in rats, but the detailed mechanism has not been explored yet. In this study we strived to characterize how FOs and FA altered the gut microbiome and related metabolome in diabetic rats by using high-throughput sequencing of 16S rRNA and gas chromatography (GC). Our results showed that FOs reduced the abundance of Lactobacillus, Ruminococcus, Oscillibacter, and Desulfovibrio, but increased the abundance of Akkermansia, Phascolarctobacterium and Turicibacter. The structure of gut microbiome in FOs treated rats was similar with healthy rats rather than diabetic rats. Likewise, FA decreased the portion of Lactobacillus, Ruminococcus, but promoted the growth of Bacteroides, Blautia, Faecalibacterium, Parabacteroides and Phascolarctobacterium. Additionally, the short-chain fatty acids (SCFAs) and branched-chain fatty acids (BCFAs), the main bacterial lipid metabolites in gut mediating host glucose metabolism, was dramatically elevated along with FOs and FA treatment. Our findings indicated that FOs and FA attenuated diabetic syndrome in rats most likely by modulating the composition and metabolism of gut microbiome. The study gives new insight into the mechanism underlying the anti-diabetes effect of functional foods as well as facilitates the development of dietary supplements for diabetic patients.